自噬是近年来肿瘤研究中的热点。课题组前期证实①miR-185-3p靶向WNT2B调控鼻咽癌（NPC）放疗抵抗性；②调控miR-185-3p和WNT2B表达改变NPC细胞自噬相关标志物水平；③NPC放疗抵抗细胞存在自噬水平改变，抑制自噬细胞放疗抵抗性下降。结合现有研究进展，我们推测：miR-185-3p靶向调控WNT2B后，介导自噬途径影响鼻咽癌的放疗抵抗性。为此，本项目拟通过：①体内外实验探讨miR-185-3p/WNT2B对NPC自噬和放疗抵抗的影响；②逆转自噬水平，检测miR-185-3p/WNT2B介导的NPC放疗抵抗是否改变；③通过临床标本验证相关指标在鼻咽癌中的临床价值。本项目的成功实施，是对miR-185-3p靶向WNT2B所介导的NPC放疗抵抗机制的深入研究，为NPC放疗抵抗机理提供新的理论基础。

Autophagy is a hot spot in the field of cancer research in recent years. In our previous study, we have found that miR-185-3p could regulate radioresistance of NPC by targeting WNT2B and confirmed both miR-185-3p and WNT2B could alter the expressions of autophagy biomarker LC3B-II. Furthermore, the radioresistant NPC cells existed a higher level of autophagy, and inhibiting autophagy could reduce the radioresistance of NPC cells. Thus, we supposed that miR-185-3p/WNT2B could regulate radioresistance of NPC via autophagy. For this purpose, the project intends to confirm the role of autophagy in miR-185-3p/WNT2B mediated radioresistance of NPC in vitro and vivo. At the same time, clinical value of the miR-185-3p/WNT2B and autophagy molecules in the pathway were tested on large group of clinical specimens. The propasal aims to discover the molecular biomarkers and therapeutic targets associated with NPC radioresistance.